参考文献/References:
[1]Gatta G,Guzzo M,Locati LD,et al.Major and minor salivary gland tumours[J].Crit Rev Oncol Hematol,2020,152(7):102959.[2]傅锦业,吴春晓,沈淑坤,等.2002-2013年上海市唾液腺恶性肿瘤流行情况分析[J].中国口腔颌面外科杂志,2019,17(2):134-140.[3]Alfieri S,Granata R,Bergamini C,et al.Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?[J].Oral Oncology,2017,66:58-63.[4]Speight PM,Takata T.New tumour entities in the 4th edition of the World Health Organization Classification of Head and Neck tumours:odontogenic and maxillofacial bone tumours[J].Virchows Arch,2018,472(3):331-339.[5]Diwakar JK,Agarwal A,Garg C,et al.A Rare Case of Mucoepidermoid Carcinoma of Parotid with Mandibular Metastasis[J].Ann Maxillofac Surg,2019,9(1):205-207.[6]Yamamoto H,Kojima T,Okanoue Y,et al.Impact of Changing Surgical Strategies on Clinical Outcomes in Patients with Parotid Carcinoma: A 53-Year Single-Institution Experience[J].Medicina (Kaunas),2021,57(8):745.[7]Lewis AG,Tong T,Maghami E.Diagnosis and Management of Malignant Salivary Gland Tumors of the Parotid Gland[J].Otolaryngol Clin North Am,2016,49(2):343-380.[8]von der Grün J,Winkelmann R,R?觟del F,et al.Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center[J].Eur Arch Otorhinolaryngol,2021,278(11):4411-4421.[9]Ferrarotto R,Mitani Y,Diao L,et al.Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors[J].J Clin Oncol,2017,35(3):352-360.[10]van Weert S,Lissenberg-Witte BI,Bloemena E,et al.Mucoepidermoid carcinoma of the head and neck:CRTC1/3 MAML 2 translocation and its prognosticators[J].Eur Arch Otorhinolaryngol,2022,279(5):2573-2581.[11]Chen Z,Ni W,Li JL,et al.The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma[J].JCI Insight,2021,6(7):e139497.[12]Okumura Y,Nakano S,Murase T,et al. Prognostic impact of CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study[J].Cancer Sci,2020,111(11):4195-4204.[13]Porcheri C,Meisel CT,Mitsiadis TA.Molecular and Cellular Modelling of Salivary Gland Tumors Open New Landscapes in Diagnosis and Treatment[J].Cancers (Basel),2020,12(11):3107.[14]Egebjerg K,Harwood CD,Woller NC,et al.HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis[J].Front Oncol,2021,11:693394.[15]Kang H,Tan M,Bishop JA,et al.Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma[J].Clin Cancer Res,2017,23(1):283-288.[16]Besch R,Berking C.POU transcription factors in melanocytes and melanoma[J].Eur J Cell Biol,2014,93(1-2):55-60.[17]Vermorken JB,Trigo J,Hitt R,et al.Open-label, uncontrolled, multicenter phase Ⅱ study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy[J].J Clin Oncol,2007,25(16):2171-2177.[18]Lee KW,Chan AB,Lo AW,et al.Erlotinib in metastatic bronchopulmonary mucoepidermoid carcinoma[J].J Thorac Oncol,2011,6(12):2140-2141.[19]Grisanti S,Amoroso V,Buglione M,et al.Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature[J].J Med Case Rep,2008,2:320.[20]Jakob JA,Kies MS,Glisson BS,et al.Phase II study of gefitinib in patients with advanced salivary gland cancers[J].Head Neck,2015,37(5):644-649.[21]Zhu G,Zhang L,Dou S,et al.Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase Ⅱ prospective study[J].Ther Adv Med Oncol,2021,13:17588359211013626.[22]Bell D,Roberts D,Kies M,et al.Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications[J].Cancer,2010,116(24):5749-5756.[23]Lassche G,van Boxtel W,Ligtenberg MJL,et al.Advances and challenges in precision medicine in salivary gland cancer[J].Cancer Treat Rev,2019,80:101906.[24]?譒teiner P,Andreasen S,Grossmann P,et al.Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands[J].Virchows Arch,2018,473(4):471-480.[25]Sahara S,Herzog AE,N?觟r JE.Systemic therapies for salivary gland adenoid cystic carcinoma[J].Am J Cancer Res,2021,11(9):4092-4110.[26]Drier Y,Cotton MJ,Williamson KE,et al.An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma[J].Nat Genet,2016,48(3):265-272.[27]Andersson MK,Afshari MK,Andrén Y,et al.Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling[J].J Natl Cancer Inst,2017,109(9):28954282.[28]Morelli MP,Calvo E,Ordo?觡ez E,et al.Prioritizing phase Ⅰ treatment options through preclinical testing on personalized tumorgraft[J].J Clin Oncol,2012,30(4):e45-e48.[29]Argiris A,Ghebremichael M,Burtness B,et al.A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)[J].Cancer,2011,117(15):3374-3382.[30]Ferrarotto R,Heymach JV.Taking it up a NOTCH: a novel subgroup of ACC is identified[J].Oncotarget,2017,8(47):81725-81726.[31]Even C,Lassen U,Merchan J,et al.Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478),in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma[J].Invest New Drugs,2020,38(2):402-409.[32]Agulnik M,Cohen EW,Cohen RB,et al.PhaseⅡstudy of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands[J].J Clin Oncol,2007,25(25):3978-3984.[33]Hitre E,Budai B,Takácsi-Nagy Z,et al.Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase Ⅱ trial[J].Br J Cancer,2013,109(5):1117-1122. [34]Wong SJ,Karrison T,Hayes DN,et al.Phase Ⅱ trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors[J].Ann Oncol,2016,27(2):318-323.[35]Alcedo JC,Fábrega JM,Arosemena JR,et al.Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases[J].Head Neck,2004,26(9):829-831.[36]Tchekmedyian V,Sherman EJ,Dunn L,et al.Phase Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma[J].J Clin Oncol,2019,37(18):1529-1537.